- Home
- KURA vs TERN Comparison
KURA vs TERN Comparison
Compare KURA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- TERN
- Stock Information
- Founded
- KURA 2014
- TERN 2017
- Country
- KURA United States
- TERN United States
- Employees
- KURA N/A
- TERN N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- TERN Health Care
- Exchange
- KURA Nasdaq
- TERN Nasdaq
- Market Cap
- KURA 561.9M
- TERN 495.2M
- IPO Year
- KURA N/A
- TERN 2021
- Fundamental
- Price
- KURA $7.34
- TERN $7.05
- Analyst Decision
- KURA Strong Buy
- TERN Buy
- Analyst Count
- KURA 13
- TERN 5
- Target Price
- KURA $24.45
- TERN $15.63
- AVG Volume (30 Days)
- KURA 1.5M
- TERN 1.1M
- Earning Date
- KURA 08-07-2025
- TERN 08-05-2025
- Dividend Yield
- KURA N/A
- TERN N/A
- EPS Growth
- KURA N/A
- TERN N/A
- EPS
- KURA N/A
- TERN N/A
- Revenue
- KURA $83,279,000.00
- TERN N/A
- Revenue This Year
- KURA $125.04
- TERN N/A
- Revenue Next Year
- KURA $83.75
- TERN N/A
- P/E Ratio
- KURA N/A
- TERN N/A
- Revenue Growth
- KURA N/A
- TERN N/A
- 52 Week Low
- KURA $5.41
- TERN $1.87
- 52 Week High
- KURA $21.57
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- KURA 67.38
- TERN 73.83
- Support Level
- KURA $5.45
- TERN $6.43
- Resistance Level
- KURA $6.74
- TERN $6.34
- Average True Range (ATR)
- KURA 0.38
- TERN 0.44
- MACD
- KURA 0.10
- TERN 0.05
- Stochastic Oscillator
- KURA 82.17
- TERN 96.07
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.